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The time it takes new drugs to penetrate the market is shrinking. David Kao suggests how drug
companies’ techniques could be used to improve safety surveillance systems
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Institutions responsible for monitoring drug safety have been
criticisedwidelyafterthewithdrawalofdrugssuchasrofecoxib
because of safety concerns. An estimated 20 million patients
received prescriptions for rofecoxib over five years before the
drug was withdrawn, and events attributable to rofecoxib may
number in tens to hundreds of thousands.
1 Regulatory bodies
such as the US Food and Drug Administration have
simultaneously been under pressure to reduce drug approval
times to ensure timely availability of new drugs. However,
concernshavebeenexpressedthatdeadlinesforapprovingdrugs
have reduced the focus on safety.
2-4
New efficiencies in drug marketing exacerbate the problem
because rapid adoption of new drugs can quickly expose large
numbers of patients to unknown risks. Here, I review trends in
drug approval times in the United States, the mechanism by
which this has been achieved, and concerns raised by this
approach. I then discuss an example of the speed with which a
new product may be adopted once approved and suggest
improvements to drug safety surveillance systems.
Trends in drug approval
Faced with staffing and budget limitations on drug approval,
the US Congress passed the Prescription Drug User Fee Act in
1992. This authorised the FDA to collect fees from drug
manufacturers and use the revenue to hire additional staff to
review drugs and improve its administrative infrastructure. In
return, the FDA established goals of reviewing 90% of priority
new drug applications within six months and 90% of standard
new drug applications within 12 months. As a result, the mean
review time in the US decreased from 33.6 months during
1979-86 to 16.1 months during 1997-2002.
5 The act has been
renewed three times since 1992, and revenues collected from
industry now account for 43% of the FDA budget for drug
oversight.
6 Similarly, the European Agency for the Evaluation
of Medicinal Products receives 75% of its funding in this
manner, and the United Kingdom’s Medicines and Healthcare
Products Regulatory Agency is entirely funded by user fees.
7-9
Critics have voiced concern over the dependence of regulatory
agenciesondrugcompaniesforoperationalfunding.
2 10Although
drugapprovaltimeshavedecreasedoverall,therelationbetween
thistrendandsubsequentpostmarketingsafetyproblemsisless
clear.
7 Drug withdrawal rates have not increased overall since
the US act, but a recent study showed that drugs approved in
the US in the two months before the mandated deadline are
more likely than those approved at other times to be withdrawn
for safety reasons, to carry a subsequent black box warning, or
to have at least one dosage voluntarily discontinued by the
manufacturer.Becausedrugsapprovedmorethanthreemonths
before or just after the deadline were not associated with the
same degree of subsequent safety problems, the authors
concluded that the deadlines may increase the likelihood of
unexpected safety problems.
4
Deficitsinpostmarketingsafetymonitoringmay,inturn,prevent
these safety concerns from being discovered for years after
approval. Depending on the success of the product, this can
meanwidespreadexposureofpatientstorisk.Rapidacceptance
of new products without concomitant improvements in
postmarketing surveillance can only exacerbate this risk.
Sitagliptin launch
Merck’s novel treatment for hyperglycaemia, sitagliptin,
provides a good example of the speed with which companies
can now get new products to market. The FDA approved
sitagliptin 3.8 years after the drug’s discovery; this compares
with five years for rofecoxib and an industry average of 14.2
years between 1990 and 1999. Once the drug was approved
Merckbeganamultifacetedmarketingcampaignthatcapitalised
on sitagliptin being a new class of drug (oral dipeptyl
peptidase-IVinhibitor).Within48hours,educationforumswere
delivered, sales representatives had their first doctor contacts,
andbroadcastsweremadebywebcastandsatellitetothousands
of healthcare providers and investigators. The product website
was functional within 90 minutes of approval, and within eight
days, Merck had reached 70% of target doctors and made first
deliveries of sitagliptin to pharmacies. Within 14 days,
discussions were completed with managed care organisations
covering around 188 million patients or 73% of the insured US
population.
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ANALYSISThe company also formed a partnership with the American
Diabetic Association to produce educational materials and
patientguidebooksandtotraindiabeteseducatorswiththegoals
ofpromptingundiagnosedpatientstoseektestingandtoidentify
cases in which treatment goals are not being met.
11 Since about
athirdofdiabeticpatientsareundiagnosedandhalfofdiagnosed
patientsarenotmeetingtreatmentgoals,thesestrategiesincrease
the potential market. Emphasis on the versatility of the drug as
bothsingleandadd-ontreatmentalsomakesthedrugmarketable
to nearly any patient with type 2 diabetes.
The success of this campaign was evident quickly. One month
afterFDAapproval,onesurveyfoundthatsitagliptinaccounted
for14%ofallnewprescriptionsgivenfortype2diabetesdrugs
by primary care doctors. Among endocrinologists, 20% of new
prescriptions for type 2 diabetes were for sitagliptin, compared
with 22% for exenatide, 19% for rosiglitazone, and 16% for
metformin.
12 Merck estimates that by the end of 2007, three
million prescriptions had been written, and sitagliptin had
becomethesecondmostprescribedbrandedoralhypoglycaemic
drug in the US. Merck reports a steady increase in sales of
sitagliptinfrom$42m(£28m;€33m)inthefinalquarterof2006
to $272m in the first quarter of 2008, putting sitagliptin on
course for $1bn in annual sales in its second year of release.
13
Marketing motivations and methods
The time required to bring a new product to market in the US
has been decreasing for the past 20 years.
14 For drug
manufacturers,rapiddeploymentandadoptionarenecessitated
byshiftsinindustryeconomicsandpublicdemand.Companies
continuallyfacethethreatoflossofrevenuebecauseofexpiring
patents, and administrative and legal costs of withdrawn or
suspended products can add millions of dollars to companies’
annual expenditures.
11 15 16 Spending on drug research and
development is aimed primarily at developing novel products
to replace these losses, ideally with new classes of drugs.
The importance of developing new products and the advantage
of being the first in a class is reflected by the decrease in time
between approval of new class drugs and follow-on drugs over
the past 30 years. Most drug classes now have at least one
competitor in advanced stages of development at the time that
thefirstdrugintheclassisapproved,andmorefollow-ondrugs
are in development at the time that the first in the class is
approvedthaneverbefore(figure⇓).Furthermore,themeanand
median interval of marketing exclusivity have decreased from
highs of 8.2 and 10.2 years respectively (n=9 drugs) during the
1960s to 1.8 and 1.2 years from 1995-8 (n=18 drugs, P<0.0001
and P=0.0005, respectively).
5 Once FDA approval is received,
companies must act quickly to establish dominance before a
competitor becomes available.
Recent years have seen major changes in drug marketing
strategies facilitated by the evolution of mass media and
prompted by changes in the relationships between
manufacturers, doctors, and patients. Doctors are more aware
oftheeffectofmarketingonprescriptionpractices,andconcerns
regardingconflictsofinteresthaveledtochangesininstitutional
policyinmanysettings,makingtraditionalmarketingtodoctors
more challenging.
17 These changes have resulted in marketing
budgets being moved to campaigns directed at funders and,
where permitted, consumers.
11 In countries such as the UK,
wheredirectadvertisingtopatientsisprohibited,thepublicmay
still access internet resources designed for patients in other
countries.
Public health initiatives regarding disease awareness and
educationhavebecomeimportantvehiclesforincreasingpublic
demandfordrugs,andengagementofhealthcarefundersisalso
a priority to ensure availability and coverage of costly new
products for patients. The success of these strategies has been
magnifiedbynewmassmediatechnologies,andcompaniesare
capitalising on their favourable cost-benefit ratio. This is
exemplified by Merck’s discussion in their 2006 and 2007
annual business briefings of the efficiency of techniques such
as video detailing and of their transition to multichannel
marketing campaigns using web, video, and customisable,
unbrandededucationresourcestoengagepotentialcustomers.
11
Thesetechniquesenabledrugcompaniestoreachmorepotential
customers faster than ever before. In most cases, this is not
harmfulandcanbenefitmanypatientsinneedofnewtreatment
options.Nevertheless,improvedinfrastructureforpostmarketing
surveillance will be crucial to minimise risk to users of these
new products.
Monitoring drug safety
Many groups have criticised the FDA for the time taken to
publicise suspected risks associated with approved products
like rofecoxib. As a result, the Federal Drug Administration
Amendments Act of 2007 included a 50% increase in fees
collected in association with the Prescription Drug Users Fee
Act, with $29.2m designated specifically for surveillance of
drug safety. FDA postmarket surveillance relies heavily on the
Adverse Event Reporting System, which collects spontaneous
reports from manufacturers, providers, and consumers that are
reviewed by scientists at the Center for Drug Evaluation and
Research. This database is publicly available and updated
quarterly, although it is difficult to extract meaningful datasets
and the data are of variable quality. The World Health
Organization Collaborating Centre for International Drug
Monitoring, also called the Uppsala Monitoring Centre,
integrates reports collected by similar systems in 83 member
countries into a single database called Vigibase, which in June
2007 contained about 3.87 million cases.
18 Vigibase is not
publicly available, although it is possible to purchase extracts
of this database for about $2500 (€1600) per drug entity and
reports of analyses are sent periodically to member
pharmacovigilance centers.
Mostadverseeventreportingsystemsrelyonvoluntaryreporting
of clinical observations and therefore are sensitive to many
biases. Lack of associated data on usage also makes it difficult
to determine the true frequency of adverse events identified,
and observers have called for development of an active
postmarketing surveillance system wherein cohorts of patients
are followed after starting a new treatment.
19 Nations with
centralised healthcare systems have some established
infrastructure to support such systems, but most use a much
smaller volume of drugs than the US. The initial draft of the
FDA’s five year drug safety plan discusses acquiring data from
organisations that have prescribing information such as drug
sales databases and the Centers for Medicare and Medicaid
Services to generate higher quality utilisation and longitudinal
outcomes data, with the goal of building a database of 100
million patients by 2012.
20 It has been estimated that with a
dataset of this size, the increased cardiovascular risk associated
with rofecoxib could have been detected independently after
two to three months rather than as a result of ongoing clinical
trials several years after approval.
21 In addition, the FDA can
now require drug companies to participate in postmarketing
safety surveillance, greatly expanding potential resources for
monitoring drug safety. Still, these improvements are expected
to take several years, and the $29.3m budget allocated for
developing drug safety monitoring represents only 1% of that
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US.
19 20
Suggestions
Emergingmarketingtechniquesuseseveralmethodsthatmight
also be used to engage a wider audience in monitoring drug
safety. The 2007 FDA Amendments Act includes some
examplessuchastherequirementthattelevisionadvertisements
mustinstructpatientsexperiencingnegativesideeffectstoreport
theirsymptomstotheFDA.
22Othertechniquesmightalsoprove
useful.Forexample,publichealthinitiativessponsoredbydrug
companies have helped providers to raise disease awareness.
Expanding this collaboration to include campaigns dedicated
to drug safety surveillance could provide healthcare
professionalswiththemarketingexpertiseandinfrastructureto
track utilisation patterns. Merck has described a shift towards
a“valuebasedpartnership”’marketingmodelthatbuildsproduct
loyalty by rewarding customers with individual benefits in the
form of convenience and improved health outcomes.
11
Maximising the direct benefit to individual patients and
providers from participating in drug safety surveillance
programmes might similarly increase voluntary involvement.
Reporting a single adverse event provides little direct benefit
to the reporting individual, but the development of tools for
managingprescriptions,whichinturncommunicatewithbroad
utilisation monitoring systems, provides patients and doctors
with personal incentives to take an active role in drug safety
monitoring by giving a useful service in return for their
participation. A multifaceted approach to postmarketing
surveillance of drug safety involving all stakeholders in
healthcareincludingproviders,payers,regulatoryagencies,and
patients seems likely to hold the most promise for maximising
thebenefitsofpharmaceuticaladvancementswhileminimising
unknown risks.
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Proportion of therapeutic classes with at least one follow-on drug in development at time the first in class was approved
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